Back to Search
Start Over
Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non‐gemfibrozil fibrate trials.
- Source :
-
Journal of Internal Medicine . May2024, Vol. 295 Issue 5, p707-710. 4p. - Publication Year :
- 2024
-
Abstract
- This article discusses the results of six randomized trials that examined the effects of fibrates and gemfibrozil on the prevention of atherosclerotic cardiovascular disease (ASCVD). The trials showed inconsistent results, and the authors sought to understand these discrepancies by examining the effects of mass changes in remnant cholesterol and LDL cholesterol. Using the Copenhagen General Population Study (CGPS) to mimic the study population of these trials, the authors compared estimated changes in ASCVD risk through mass changes in cholesterol with the observed changes in the original trials. The results suggest that mass changes in total atherogenic cholesterol can explain the results of these trials, regardless of whether statins were used or not. The authors conclude that to reduce ASCVD, cholesterol-lowering agents should aim to reduce the total mass of atherogenic cholesterol. [Extracted from the article]
- Subjects :
- *CHOLESTEROL content of food
*LDL cholesterol
*HDL cholesterol
Subjects
Details
- Language :
- English
- ISSN :
- 09546820
- Volume :
- 295
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Journal of Internal Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 176497184
- Full Text :
- https://doi.org/10.1111/joim.13771